New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review

AR Losito, F Raffaelli, P Del Giacomo, M Tumbarello - Antibiotics, 2022 - mdpi.com
P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

GL Daikos, CA da Cunha, GM Rossolini, GG Stone… - Antibiotics, 2021 - mdpi.com
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range
of serious infections that are often challenging to treat, as this pathogen can express multiple …

Current and potential therapeutic options for infections caused by difficult-to-treat and pandrug resistant gram-negative bacteria in critically ill patients

H Giamarellou, I Karaiskos - Antibiotics, 2022 - mdpi.com
Carbapenem resistance in Gram-negative bacteria has come into sight as a serious global
threat. Carbapenem-resistant Gram-negative pathogens and their main representatives …

Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and …

YL Lee, WC Ko, PR Hsueh - Antimicrobial agents and …, 2022 - Am Soc Microbiol
Pseudomonas aeruginosa is a common pathogen that is associated with multidrug-resistant
(MDR) and carbapenem-resistant (CR) phenotypes; therefore, we investigated its resistance …

Alternatives therapeutic approaches to conventional antibiotics: Advantages, limitations and potential application in medicine

H Alaoui Mdarhri, R Benmessaoud, H Yacoubi, L Seffar… - Antibiotics, 2022 - mdpi.com
Resistance to antimicrobials and particularly multidrug resistance is one of the greatest
challenges in the health system nowadays. The continual increase in the rates of …

A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for …

M Gatti, R Pascale, PG Cojutti, M Rinaldi… - International Journal of …, 2023 - Elsevier
Objectives To describe the pharmacokinetic/pharmacodynamic (PK/PD) behaviour of
continuous infusion (CI) ceftazidime-avibactam and the microbiological outcome in a case …

Antibiotic therapy strategies for treating gram-negative severe infections in the critically Ill: A narrative review

A Corona, V De Santis, A Agarossi, A Prete… - Antibiotics, 2023 - mdpi.com
Introduction: Not enough data exist to inform the optimal duration and type of antimicrobial
therapy against GN infections in critically ill patients. Methods: Narrative review based on a …

Microbiological, clinical, and PK/PD features of the new anti-Gram-negative antibiotics: β-lactam/β-lactamase inhibitors in combination and cefiderocol—an all …

L Principe, T Lupia, L Andriani, F Campanile… - Pharmaceuticals, 2022 - mdpi.com
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly
true for Gram-negative bacteria. Over the last decade, the strategy to develop new β …

How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the …

E Carrara, PA Grossi, A Gori… - The Lancet Infectious …, 2024 - thelancet.com
Promoting the optimal use of antibiotics through evidence-based recommendations should
be regarded as a crucial step in the global fight against antimicrobial resistance. Within this …

New antimicrobial treatment options for severe Gram-negative infections

L Hetzler, MH Kollef, V Yuenger, ST Micek… - Current Opinion in …, 2022 - journals.lww.com
Severe/MDR Gram-negative infections continue to be important infections due to their
impact on patient outcomes, especially in critically ill and immunocompromised hosts. The …